Mineralys Therapeutics Inc’s recent filing unveils that its CFO and Secretary Levy Adam Scott unloaded Company’s shares for reported $97864.0 on Jan 13 ’25. In the deal valued at $9.10 per share,10,757 shares were sold. As a result of this transaction, Levy Adam Scott now holds 226,097 shares worth roughly $1.98 million.
Then, Congleton Jon sold 18,333 shares, generating $166,082 in total proceeds. Upon selling the shares at $9.06, the Chief Executive Officer now owns 877,608 shares.
Before that, Congleton Jon bought 18,333 shares. Mineralys Therapeutics Inc shares valued at $166,083 were divested by the Officer at a price of $9.06 per share.
H.C. Wainwright initiated its Mineralys Therapeutics Inc [MLYS] rating to a Buy in a research note published on July 10, 2024; the price target was $30. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in early April with a ‘”a Buy”‘ rating. Wells Fargo began covering MLYS with “an Overweight” recommendation on March 07, 2023. Stifel started covering the stock on March 07, 2023. It rated MLYS as “a Buy”.
Price Performance Review of MLYS
On Tuesday, Mineralys Therapeutics Inc [NASDAQ:MLYS] saw its stock fall -5.30% to $8.76. Over the last five days, the stock has lost -8.75%. Mineralys Therapeutics Inc shares have fallen nearly -28.84% since the year began. Nevertheless, the stocks have fallen -44.06% over the past one year. While a 52-week high of $16.91 was reached on 01/07/25, a 52-week low of $8.58 was recorded on 02/25/25. SMA at 50 days reached $10.79, while 200 days put it at $12.18.
Levels Of Support And Resistance For MLYS Stock
The 24-hour chart illustrates a support level at 8.24, which if violated will result in even more drops to 7.72. On the upside, there is a resistance level at 9.28. A further resistance level may holdings at 9.81. The Relative Strength Index (RSI) on the 14-day chart is 35.21, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.55, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 81.78%. Stochastics %K at 19.50% indicates the stock is a buying.
The most recent change occurred on March 07, 2023 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $32 price target.
